Masimo

MASI

Market cap $7.72B

Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The mean of analysts' price targets for Masimo (MASI) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

IRVINE, Calif. , Nov. 18, 2025 /PRNewswire/ -- A team from Knobbe Martens led medical device pioneer Masimo (NASDAQ: MASI) to a victory over Apple in a dispute involving Masimo's patented heart monitoring technology.

DRC congratulates Knobbe Martens on a decisive jury verdict awarding its client Masimo more than $634 million in an Apple Watch patent infringement case.

Sold 45,000 shares in Masimo, reducing reported position by $7,569,900 Transaction represents a 4.0301% change in 13F reportable assets under management (AUM) Post-trade stake: 0 shares, $0 reported value The position was previously 4.0699% of the fund's AUM as of the prior quarter, marking a full exit this period

A federal jury in California ruled Friday that Apple must pay medical device maker Masimo $634 million for infringing a patent on blood oxygen monitoring technology.

A federal jury in California said on Friday that Apple owes medical-monitoring technology company Masimo $634 million for infringing a patent covering blood-oxygen reading technology.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today issued the following statement in response to the jury verdict announced in the U.S. District Court for the Central District of California, which confirmed the validity of Masimo Patent No. 10,433,776, found Apple infringed this patent, and awarded Masimo $634 million in damages: “We are pleased by this outcome, and appreciate the time and attention given to our case by the court and the jury. This is a significant win in our ongoing.

Masimo (MASI) possesses solid growth attributes, which could help it handily outperform the market.